Intas Pharma May Offload 10 Percent to Raise Rs200 Crore From Market (India)
This article was originally published in PharmAsia News
Intas Pharmaceuticals is reportedly considering an initial public offering (IPO) on the Indian market. Expected to be worth about 10 percent of the company, the IPO would be the biggest public offering by an Indian drug manufacturer on record. Intas is also one of the fastest growing companies on the market, expanding at a rate of 20 percent to 25 percent. Much of that growth is due to the company's solid pipeline. Currently, Intas boasts therapies in a number of areas including central nervous system, cardiovascular, diabetes, gastroentrology, urology, and pain relief. Although the mid-size company already has a presences in South-East Asia, Africa, the U.S., Europe, and Latin America, Intas' public offering could position it to be a leader in the domestic market. (Click here for more
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.